-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates FinServ Acquisition Corp.’s Directors and Officers for Breach of Fiduciary Duties – KPLT, FSRV

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of FinServ Acquisition Corp. (“FinServ”) (NASDAQ: FSRV); n/k/a Katapult Holdings, Inc. (“Katapult”) (NASDAQ: KPLT) breached their fiduciary duties to FinServ’s shareholders. If you were a FinServ shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether FinServ’s board of directors or executive officers breached their duties of disclosure, duties of candor, and requirements to act in good faith, and whether FinServ’s shareholders suffered damages as a result.

On June 7, 2021, FinServ shareholders of record as of May 11, 2021, approved a merger between FinServ and Katapult.

On August 10, 2021, Katapult announced quarterly financial results, which included disappointing revenue and earnings numbers. Katapult also pulled all future guidance. The stock has continued to decline.

Overall, the stock price has declined by over 90% since the merger, with shares currently trading at $0.96 per share.

What You Can Do
If you were a FinServ shareholder, you may have legal claims against FinServ’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982, or jpettigrew@scott-scott.com.

About Scott+Scott
Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:KPLT

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

THE ENSIGN GROUP, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates The Ensign Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ENSG

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of The Ensign Group, Inc. (NASDAQ: ENSG) failed to manage The Ensign Group in an acceptable manner, breaching their fiduciary duties to Ensign Group, and whether Ensign Group and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On June 11, 2026, Muddy Waters Research...

CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Celsius Holdings, Inc. (NASDAQ: CELH) failed to manage Celsius in an acceptable manner, breaching their fiduciary duties to Celsius, and whether Celsius and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On June 4, 2026, the Office of the Texas Attorney Genera...

ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On March 24, 2026, Culper Research pu...
Back to Newsroom